Roche invested around 719 million euros in Germany in the 2025 financial year, reaching an all-time high. Total sales rose by 4.7 percent to around 8.9 billion euros. The company thus reaffirmed its long-term commitment to Germany as a business location and made a contribution to the high-tech agenda as well as to the future pharmaceutical and medical technology strategy of the German government.

The Pharmaceuticals division recorded growth of 6.3 percent to 2.2 billion euros, driven by innovative therapies such as Vabysmo, Ocrevus, Evrysdi and Polivy, which reflect high demand in an aging society. The diagnostics division developed stably and reached around 909 million euros (minus 1 percent). Declines in the blood glucose test strips and coagulation self-management business due to technological changes were largely offset by solid growth in the core business.

Group deliveries from German sites to the global Roche Group rose by 5 percent to 5.8 billion euros. This underlines the strategic importance of Germany as a technology and production hub, it said. At the end of 2025, Roche had 18,594 employees in Germany (up 338), including 643 trainees. According to Prognos AG, around 56,000 jobs depend directly or indirectly on Roche.

One example of the investments is the Diagnostics Innovation Center in Penzberg, which opened on February 12, 2026, with a volume of 300 million euros. Thanks to intelligent networking, fully automated processes and modern robotics, the development time of central steps in test development has been reduced by 30 percent. Daniela Kahlert, Managing Director of Roche Diagnostics Germany, emphasized the role of early diagnostics as the key to effective therapies – for example in cancer or neurodegenerative diseases – and thus also to greater efficiency in the healthcare system.

Dr. Claudia Fleischer, Managing Director Roche Diagnostics GmbH, explained that Roche had kept its investment promise even under difficult conditions. Since 2020, almost 3.8 billion euros have been invested and over 1,800 new jobs have been created. The investments are long-term and are aimed at technology, locations and qualified employees. However, bureaucracy, over-regulation and slow approval procedures caused massive additional costs and weakened international competitiveness.

Dr. Daniel Steiners, Member of the Executive Board of Roche Pharma AG, emphasized the strategic importance of the industrial healthcare industry. The industry is a growth driver, creates high-quality jobs and stabilises social security systems. In view of volatile global environments, it is also becoming increasingly important for national security and technological sovereignty. Reforms in the USA – for example in the FDA and the strengthening of domestic production – could also have consequences for Germany. Steiners called for planning security, accelerated approval procedures, consistent digitalisation, innovation-friendly market access conditions and appropriate remuneration for innovations.

Roche remains one of the largest employers and investors in the German life sciences industry.

The article was originally published by LabNews. Responsible for the content is LabNews Media LLC.

Read Also:

Verification of ferritin on Roche cobas® 8000 C702 and comparison with E801 – MedLabPortal

Focus on efficiency and precision: The Roche Diagnostics reagent portfolio – MedLabPortal

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.